Abstract 1705P
Background
After first approval of a new drug, it may subsequently be approved for additional indications. The number of drugs approved for such supplemental indications has increased, however, their added therapeutic benefit is unclear. We analyzed the therapeutic value of supplemental indications compared to first indications for drugs approved in the US and Europe (2011-2020).
Methods
We identified first and supplemental indications that were approved by the FDA and EMA. Therapeutic value ratings were obtained from France and Germany. We used descriptive statistics to analyze the unadjusted proportion of first and supplemental indications rated highly by the French or German health authorities. To obtain adjusted estimates of the probability for supplemental indications to be rated highly, we used Poisson regression analyses.
Results
124 first and 335 supplemental indications approved by the FDA, and 88 first and 215 supplemental indications by the EMA were included, the largest subset for cancer disorders. Therapeutic ratings were available for 107 (86%) first and 179 (53%) supplemental indications in the US, and 87 (99%) first and 184 (86%) supplemental indications in Europe. Among FDA-approved indications with available ratings, 41% (44/107) had high therapeutic value ratings for first, compared with 34% (61/179) for supplemental indications. In Europe, 47% (41/87) of first and 36% (67/184) of supplemental indications had high therapeutic value ratings. Among FDA approvals, when the sample was restricted to the first three approved indications, second indication approvals were 36% less likely to have a high value rating (RR=0.64, 95%CI, 0.43-0.96) and third indication approvals were 45% less likely (RR=0.55, 95%CI, 0.29-1.01) when compared to the first indication approval. Similar findings were observed for Europe and when weighting by the inverse number of indications for each drug.
Conclusions
The proportion of supplemental indications rated as having high therapeutic value was substantially lower compared to first indications. When indications do not offer added therapeutic value over other available treatments, that information should be clearly communicated to patients and physicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
K.N. Vokinger.
Funding
Swiss Cancer Research Foundation, Swiss National Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22